Violet Defense Reports Effectiveness of UV Technology Unchanged After CDC Revises COVID-19 Guidance

Violet Defense advises an April update from the Centers for Disease Control and Prevention (CDC) significantly changes the agency’s guidance on how they believe the COVID-19 virus is transmitted.

But UV light disinfection products, like the patented technology from Violet Defense, still effectively address its key pathogen transmission pathways.

SARS-CoV-2, the virus behind COVID-19, most often spreads through droplets found in the air, where traditional chemical cleaning products are ineffective at killing germs, although, the CDC still recommends frequent disinfection of high-touch surfaces in areas with high risk of transmission of COVID-19 or low levels of mask-wearing. Given this guidance, finding solutions that can easily address both air and surface disinfection is prudent.

Violet Defense, makers of commercial UV disinfection products, offers the only known Pulsed Xenon disinfection solution that can be installed for fully automatic disinfection. It provides reliable and continuous disinfection of any area, covering both the air and surfaces in 30-minute cycles. The technology is proven through third-party lab testing to effectively kill up to 99.9% of SARS-CoV-2, MRSA, Norovirus, E.coli, and Salmonella. Violet Defense also now offers a series of continuous UV air disinfection products from PURO Air aimed at HVAC systems, in-duct and in-room air disinfection even in occupied spaces.

“UV disinfection technology is an effective and affordable method to kill dangerous germs that are found both in the air and on surfaces and should be considered as part of a multi-layered disinfection strategy,” said Terrance Berland, Chief Executive Officer of Violet Defense. “Even after we move past the threat of COVID-19, germ-killing technology will be vital to protect busy public places such as schools, fire and police departments, museums, and other large venues where people regularly congregate. Moving forward, we fully expect that UV technology will be a particularly valuable investment to provide our world’s critical infrastructure with protection against the next outbreak or even our annual flu season,” Berland said.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”